# US 2004/0023995 A1 · Pyridopyrimidine compounds and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023995 A1
- Document ID: US20040023995A1
- Status: Published application
- Kind: A1
- Application number: 09/859,503
- Filed: 2001-05-18
- Published: 2004-02-05
- Earliest claimed: 2001-05-18
- Assignees: Cell Therapeutics, Inc.
- Inventors: Marc J. McKennon; J. Peter Klein; Michael Coon
- Web page: https://patentgrep.com/patent/US20040023995A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

## Claims

### Claim 1

A therapeutic compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula:
31
wherein:
R1 is selected from a member of the group consisting of hydrogen, hydroxyl, methoxyl, N—OH, acylamino group, cyano group, sulfo, sulfonyl, sulfinyl, sulfhydryl (mercapto), sulfeno, sulfanilyl, sulfamyl, sulfamino, and phosphino, phosphinyl, phospho, phosphono and —NRaRb, wherein each of Ra and Rb may be the same or different and each is selected from the group consisting of hydrogen and optionally substituted: C(1-20)alkyl, C(1-20)cycloalkyl, C(1-20)alkenyl, C(1-20)cycloalkenyl, C(1-20)alkynyl, aryl, heteroaryl, and heterocyclic group.
R2 and R3 are independently selected from a member of the group consisting of halo, thio, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylthio, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraminoalkyl, C(1-20)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(1-20)alkoxyl, C(1-20)alkoxyalkyl, C(1-20)dialkoxyalkyl, and —NRaRb.
R4 may be hydrogen or an optionally substituted member of the group consisting of C(1-20)alkyl, C(1-20)cycloalkyl, C(1-20)alkenyl, C(1-20)cycloalkenyl, C(1-20)alkynyl, aryl, heteroaryl, and heterocyclic group.

### Claim 2 (depends on 1)

The therapeutic compound of claim 1, wherein R2 and R3 are independently selected from a member of the group consisting of hydrogen, halo, thio, oxo, C(1-10)alkyl, C(1-10)hydroxyalkyl, C(1-10)thioalkyl, C(1-10)alkylthio, C(1-10)alkylamino, C(1-10)alkylaminoalkyl, C(1-10)aminoalkyl, C(1-10)aminoalkoxyalkenyl, C(1-10)aminoalkoxyalkynyl, C(1-10)diaminoalkyl, C(1-10)triaminoalkyl, C(1-10)tetraminoalkyl, C(1-10)aminotrialkoxyamino, C(1-10)alkylamido, C(1-10)alkylamidoalkyl, C(1-10)amidoalkyl, C(1-10)acetamidoalkyl, C(1-10)alkenyl, C(1-10)alkynyl, C(1-10)alkoxyl, C(1-10)alkoxyalkyl, and C(1-10)dialkoxyalkyl.

### Claim 3 (depends on 1)

The therapeutic compound of claim 1, wherein R2 and R3 are selected from the group consisting of methyl, ethyl, oxo, isopropyl, n-propyl, isobutyl, n-butyl, t-butyl, 2-hydroxyethyl, 3-hydroxypropyl, 3-hydroxy-n-butyl, 2-methoxyethyl, 4-methoxy-n-butyl, 5-hydroxyhexyl, 2-bromopropyl, 3-dimethylaminobutyl, 4-chloropentyl, methylamino, aminomethyl, and methylphenyl.

### Claim 4 (depends on 1)

The therapeutic compound of claim 1, wherein each of R2 and R3 is substituted with one or more members of the group consisting of hydroxyl, methyl, carboxyl, furyl, furfuryl, biotinyl, phenyl, naphthyl, amino group, amido group, carbamoyl group, cyano group, sulfo, sulfonyl, sulfinyl, sulfhydryl, sulfeno, sulfanilyl, sulfamyl, sulfamino, phosphino, phosphinyl, phospho, phosphono, N—OH, —Si(CH3)3, C(1-3)alkyl, C1-3)hydroxyalkyl, C1-3)thioalkyl, C1-3)alkylamino, benzyldihydrocinnamoyl group, benzoyldihydrocinnamido group, optionally substituted heterocyclic group and optionally substituted carbocyclic group.

### Claim 5 (depends on 4)

The therapeutic compound of claim 4, wherein the heterocyclic group or carbocyclic group is substituted with one or more members of the group consisting of halo, hydroxyl, nitro, SO2NH2, C(1-6)alkyl, C(1-6)haloalkyl, C(1-6)alkoxyl, C(1-11)alkoxyalkyl, C(1-6)alkylamino, and C(1-6)aminoalkyl.

### Claim 6 (depends on 4)

The therapeutic compound of claim 4, wherein the heterocyclic group is a member selected from the group consisting of acridinyl, aziridinyl, azocinyl, azepinyl, benzimidazolyl, benzodioxolanyl, benzofuranyl, benzothiophenyl, carbazole, 4a H-carbazole, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, dioxoindolyl, furazanyl, furyl, furfuryl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthalenyl, naphthyridinyl, norbornanyl, norpinanyl, octahydroisoquinolinyl, oxazolidinyl, oxazolyl, oxiranyl, perimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phenyl, phthalazinyl, piperazinyl, piperidinyl, 4-piperidonyl, piperidyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyrenyl, pyridazinyl, pyridinyl, pyridyl, pyridyl, pyrimidinyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolonyl, pyrrolyl, 2H-pyrrolyl, quinazolinyl, 4H-quinolizinyl, quinolinyl, quinoxalinyl, quinuclidinyl, β-carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 2H-,6H-1,5,2-dithiazinyl, thianthrenyl, thiazolyl, thienyl, thiophenyl, triazinyl, xanthenyl and xanthinyl.

### Claim 7 (depends on 4)

The therapeutic compound of claim 4, wherein the carbocyclic group is a member selected from the group consisting of adamantyl, anthracenyl, benzamidyl, benzyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.1]hexanyl, bicyclo[2.2.2]octanyl, bicyclo[3.2.0]heptanyl, bicyclo[4.3.0]nonanyl, bicyclo[4.4.0]decanyl, biphenyl, biscyclooctyl, cyclobutyl, cyclobutenyl, cycloheptyl, cycloheptenyl, cyclohexanedionyl, cyclohexenyl, cyclohexyl, cyclooctanyl, cyclopentadienyl, cyclopentanedionyl, cyclopentenyl, cyclopentyl, cyclopropyl, decalinyl, 1,2-diphenylethanyl, indanyl, 1-indanonyl, indenyl, naphthyl, napthlalenyl, phenyl, resorcinolyl, stilbenyl, tetrahydronaphthyl, tetralinyl, tetralonyl, and tricyclododecanyl.

### Claim 8

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
32

### Claim 9

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
33

### Claim 10

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
34

### Claim 11

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
35

### Claim 12

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
36

### Claim 13

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
37

### Claim 14

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
38

### Claim 15

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
39

### Claim 16

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
40

### Claim 17

A compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the formula:
41

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.

### Claim 19 (depends on 1)

A method for inhibiting a cellular process or an activity mediated by cytokine, the method comprising:
(a) contacting cytokine responsive cells with a compound as defined in claim 1; and
(b) determining that the cellular process or activity mediated by the cytokine is inhibited.

### Claim 20 (depends on 19)

The method of claim 19, wherein step (a) is carried out in vitro.

### Claim 21 (depends on 19)

The method of claim 19, wherein said cellular process is the differentiation of naïve T cells into Th1 or T1 cells.

### Claim 22 (depends on 19)

The method of claim 19, wherein said cellular process is the differentiation of naïve T cells into Th2 or T2 cells.

### Claim 23 (depends on 19)

The method of claim 19, wherein said activity is the secretion of proinflammatory cytokines.

### Claim 24 (depends on 19)

The method of claim 19, wherein said activity is the secretion of anti-inflammatory cytokines.

### Claim 25 (depends on 19)

The method of claim 19, wherein said activity is the secretion of a cytokine selected from the group consisting of tumor necrosis factor, colony stimulating factor, interferon, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, transforming growth factor, oncostatin M, leukemia inhibiting factor, and platelet activating factor.

### Claim 26 (depends on 25)

The method of claim 25, wherein said cytokine is IL-12.

### Claim 27 (depends on 25)

The method of claim 25, wherein said cytokine is IL-4.

### Claim 28 (depends on 1)

A method for treating a T1 cell-mediated inflammatory response in a mammal in need of such treatment, the method comprising administering to the mammal a therapeutically effective amount of the compound of claim 1, wherein said compound is capable of inhibiting an IL-12 mediated cellular process or activity, thereby inhibiting the inflammatory response.

### Claim 29 (depends on 28)

The method of claim 28, wherein the inflammatory response is associated with a disease or condition selected from the group consisting of chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis, asthma and autoimmune disorders.

### Claim 30 (depends on 28)

The method of claim 28, wherein said autoimmune disorder is selected from Type-1 IDDM, multiple sclerosis, rheumatoid arthritis, uveitis, inflammatory bowel disease, lupus disorders, and acute and chronic graft-versus-host disease.

### Claim 31 (depends on 28)

The method of claim 28, wherein said mammal is a human.

### Claim 32 (depends on 1)

A method for treating a T2 cell-mediated anti-inflammatory response in a mammal in need of such treatment, the method comprising administering to the mammal a therapeutically effective amount of the compound of claim 1, wherein said compound is capable of inhibiting an IL-4 mediated cellular process or activity, thereby inhibiting anti-inflammatory response.

### Claim 33 (depends on 32)

The method of claim 32, wherein the anti-inflammatory response is associated with a disease or condition selected from the group consisting of asthma, atopic dermatitis, hay fever, eczema, urticaria and food allergy.

### Claim 34 (depends on 32)

The method of claim 32, wherein said disease is asthma.

### Claim 35 (depends on 32)

The method of claim 32, wherein said mammal is a human.

### Claim 36 (depends on 1)

A method for preventing or treating NIDDM comprising a step of administering to a subject in need of such treatment a therapeutically effective amount of the compound of claim 1.
